Skip to main content

Advertisement

SpringerLink
Log in

Current Indications for Photodynamic Therapy in Retina and Ocular Oncology

  • Retina (Raquel Goldhardt, Section Editor)
  • Published:
Current Ophthalmology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of this review is to summarize the current indications for photodynamic therapy (PDT) in the treatment of retinal diseases and intraocular tumors.

Recent Findings

The recent introduction of new imaging modalities such as optical coherence tomography angiography and swept-source optical coherence tomography has enabled the quick and non-invasive identification of certain retinal conditions that benefit from PDT. Furthermore, recent reports in the literature have confirmed the role of PDT as an effective treatment modality for selected intraocular tumors.

Summary

While the use of PDT has decreased since its introduction due to the advent of intravitreal anti-vascular endothelial growth factor therapy, there is still a role for this modality in several retinal conditions and intraocular tumors including central serous chorioretinopathy, pachychoroid neovasculopathy, polypoidal choroidal vasculopathy, choroidal neovascularization associated with choroidal nevus, choroidal hemangioma, choroidal metastasis, and retinal hemangioblastoma. PDT should be employed in the appropriate settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. Ziemssen F, Heimann H. Evaluation of verteporfin pharmacokinetics-redefining the need of photosensitizers in ophthalmology. Expert Opin Drug Metab Toxicol. 2012;8(8):1023–41. https://doi.org/10.1517/17425255.2012.701617.

    Article  CAS  PubMed  Google Scholar 

  2. Newman DK. Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond). 2016;30(2):202–10. https://doi.org/10.1038/eye.2015.251.

    Article  CAS  Google Scholar 

  3. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch Ophthalmol. 1999;117(10):1329–45.

  4. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology. 2001;108(5):841–52. https://doi.org/10.1016/s0161-6420(01)00544-9.

  5. Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012;119(5):992–1000. https://doi.org/10.1016/j.ophtha.2012.02.002.

    Article  PubMed  Google Scholar 

  6. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology. 2001;108(5):841–52.

  7. Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120(9):1944-5.e1.

    Article  Google Scholar 

  8. Saviano S, Piermarocchi R, Leon PE, Mangogna A, Zanei A, Cavarzeran Sc F, et al. Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one- year follow-up controlled study. Int J Ophthalmol. 2014;7(2):335–9.

    PubMed  PubMed Central  Google Scholar 

  9. Lai TY, Wong RL, Chan WM. Long-term outcome of half-dose verteporfin photodynamic therapy for the treatment of central serous chorioretinopathy (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2015;113:T8.

    PubMed  PubMed Central  Google Scholar 

  10. Ma J, Meng N, Xu X, Zhou F, Qu Y. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014;92(8):e594-601. https://doi.org/10.1111/aos.12482.

    Article  CAS  PubMed  Google Scholar 

  11. Doepfner JM, Michels S, Graf N, Becker MD, Freiberg JF. Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study. Clin Ophthalmol. 2018;12:1301–9.

    Article  CAS  Google Scholar 

  12. Peiretti E, Caminiti G, Serra R, Querques L, Pertile R, Querques G. Anti-vascular endothelial growth factor therapy versus photodynamic therapy in the treatment of choroidal neovascularization secondary to central serous choriortinopathy. Retina. 2018;38(8):1526–32.

    Article  CAS  Google Scholar 

  13. Matsumoto H, Mukai R, Kikuchi Y, Morimoto M, Akiyama H. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol. 2020;64(2):203–9. https://doi.org/10.1007/s10384-020-00722-7.

    Article  CAS  PubMed  Google Scholar 

  14. Wong CW, Cheung CM, Mathur R, Li X, Chan CM, Yeo I, et al. Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: retrospective study and systematic review. Retina. 2015;35(8):1577–93. https://doi.org/10.1097/iae.0000000000000499.

    Article  PubMed  Google Scholar 

  15. •• Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935–42. https://doi.org/10.1001/jamaophthalmol.2020.2443. This 24-month, double-masked, multicenter, randomized clinical trial was conducted in patients with polypoidal choroidal vasculopathy and compared treatment outcomes of ranibizumab plus prompt photodynamic combination therapy with ranibizumab monotherapy.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Pellegrini M, Corvi F, Say EAT, Shields CL, Staurenghi G. Optical coherence tomography angiography features of choroidal neovascularization associated with choroidal nevus. Retina. 2018;38(7):1338–46. https://doi.org/10.1097/iae.0000000000001730.

    Article  PubMed  Google Scholar 

  17. Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina. 2016;36(3):499–516. https://doi.org/10.1097/iae.0000000000000742.

    Article  PubMed  Google Scholar 

  18. Bousquet E, Bonnin S, Mrejen S, Krivosic V, Tadayoni R, Gaudric A. Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina. 2018;38(3):629–38. https://doi.org/10.1097/iae.0000000000001580.

    Article  PubMed  Google Scholar 

  19. Dansingani KK, Balaratnasingam C, Klufas MA, Sarraf D, Freund KB. Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol. 2015;160(6):1243-54.e2. https://doi.org/10.1016/j.ajo.2015.08.028.

    Article  PubMed  Google Scholar 

  20. Chong Teo KY, Sadda SR, Gemmy Cheung CM, Chakravarthy U, Staurenghi G, Invernizzi A, et al. Non ICGA treatment criteria for suboptimal anti VEGF response for polypoidal choroidal vasculopathy: APOIS PCV Workgroup Report 2. Ophthalmol Retina. 2021. https://doi.org/10.1016/j.oret.2021.04.002.

    Article  PubMed  Google Scholar 

  21. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119(2):198–207.

    CAS  PubMed  Google Scholar 

  22. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131(5):541–60. https://doi.org/10.1016/s0002-9394(01)00967-9.

  23. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology. 2003;110(4):667–73. https://doi.org/10.1016/s0161-6420(02)01998-x.

    Article  PubMed  Google Scholar 

  24. Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123(4):448–57. https://doi.org/10.1001/archopht.123.4.448.

    Article  PubMed  Google Scholar 

  25. Kaiser PK. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Curr Med Res Opin. 2009;25(8):1853–60. https://doi.org/10.1185/03007990903038616.

    Article  CAS  PubMed  Google Scholar 

  26. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–44. https://doi.org/10.1056/NEJMoa062655.

    Article  CAS  PubMed  Google Scholar 

  27. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31. https://doi.org/10.1056/NEJMoa054481.

    Article  CAS  PubMed  Google Scholar 

  28. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012;119(5):1001–10. https://doi.org/10.1016/j.ophtha.2012.02.003.

    Article  PubMed  Google Scholar 

  29. • Gao Y, Yu T, Zhang Y, Dang G. Anti-VEGF monotherapy versus photodynamic therapy and anti-VEGF combination treatment for neovascular age-related macular degeneration: a meta-analysis. Invest Ophthalmol Vis Sci. 2018;59(10):4307–17. https://doi.org/10.1167/iovs.17-23747. This meta-analysis of randomized controlled trials compared the efficacy and safety of anti-VEGF monotherapy with anti-VEGF and photodynamic therapy in neovascular age-related macular degeneration.

    Article  CAS  PubMed  Google Scholar 

  30. Tozer K, Roller AB, Chong LP, Sadda S, Folk JC, Mahajan VB, et al. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology. 2013;120(10):2029–34. https://doi.org/10.1016/j.ophtha.2013.03.016.

    Article  PubMed  Google Scholar 

  31. Park UC, Kim BH, Choe HR, Yeon DY, Yu HG. Long-term results of rescue photodynamic therapy for type 1 neovascularization refractory to anti-vascular endothelial growth factor. Acta Ophthalmol. 2020. https://doi.org/10.1111/aos.14719.

    Article  PubMed  Google Scholar 

  32. • Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye (Lond). 2019;33(1):14–33. https://doi.org/10.1038/s41433-018-0158-4. This review article covered the clinical and imaging features and management considerations of the entities in the pachychoroid spectrum, with a focus on the current understanding of the pathogenesis and the most recent findings regarding pachychoroid disease.

    Article  Google Scholar 

  33. Ferrara D, Mohler KJ, Waheed N, Adhi M, Liu JJ, Grulkowski I, et al. En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy. Ophthalmology. 2014;121(3):719–26. https://doi.org/10.1016/j.ophtha.2013.10.014.

    Article  PubMed  Google Scholar 

  34. Izumi T, Koizumi H, Maruko I, Takahashi Y, Sonoda S, Sakamoto T, et al. Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. Br J Ophthalmol. 2017;101(4):433–7. https://doi.org/10.1136/bjophthalmol-2016-308921.

    Article  PubMed  Google Scholar 

  35. Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010;117(9):1792–9. https://doi.org/10.1016/j.ophtha.2010.01.023.

    Article  PubMed  Google Scholar 

  36. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23(3):288–98. https://doi.org/10.1097/00006982-200306000-00002.

    Article  PubMed  Google Scholar 

  37. Koytak A, Bayraktar H, Ozdemir H. Fluorescein angiography as a primary guide for reduced-fluence photodynamic therapy for the treatment of chronic central serous chorioretinopathy. Int Ophthalmol. 2020;40(7):1807–13. https://doi.org/10.1007/s10792-020-01350-3.

    Article  PubMed  Google Scholar 

  38. Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2014;121(5):1073–8. https://doi.org/10.1016/j.ophtha.2013.11.040.

    Article  PubMed  Google Scholar 

  39. Ruiz-Moreno JM, Lugo FL, Armadá F, Silva R, Montero JA, Arevalo JF, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol. 2010;88(3):371–6. https://doi.org/10.1111/j.1755-3768.2008.01408.x.

    Article  PubMed  Google Scholar 

  40. Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Gregorio T, Cachulo ML, et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina. 2013;33(2):309–15. https://doi.org/10.1097/IAE.0b013e3182670fbe.

    Article  CAS  PubMed  Google Scholar 

  41. Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010;149(2):307-15.e2. https://doi.org/10.1016/j.ajo.2009.08.026.

    Article  PubMed  Google Scholar 

  42. Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28(1):85–93. https://doi.org/10.1097/IAE.0b013e318156777f.

    Article  PubMed  Google Scholar 

  43. Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, et al. A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2016;170:91–9. https://doi.org/10.1016/j.ajo.2016.07.026.

    Article  PubMed  Google Scholar 

  44. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115(10):1756–65. https://doi.org/10.1016/j.ophtha.2008.04.014.

    Article  PubMed  Google Scholar 

  45. • van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE Trial. Ophthalmology. 2018;125(10):1547–55. https://doi.org/10.1016/j.ophtha.2018.04.021. This open-label, multicenter, randomized controlled clinical trial compared the anatomical and functional efficacy and safety of half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy.

    Article  PubMed  Google Scholar 

  46. Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina (Philadelphia, Pa). 2015;35(1):1–9. https://doi.org/10.1097/iae.0000000000000331.

    Article  CAS  Google Scholar 

  47. Chhablani J, Kozak I, Pichi F, Chenworth M, Berrocal MH, Bedi R, et al. Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. Retina. 2015;35(12):2489–97. https://doi.org/10.1097/iae.0000000000000655.

    Article  CAS  PubMed  Google Scholar 

  48. Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol. 2018;62(2):144–50. https://doi.org/10.1007/s10384-018-0562-0.

    Article  CAS  PubMed  Google Scholar 

  49. Kitajima Y, Maruyama-Inoue M, Ito A, Sato S, Inoue T, Yamane S, et al. One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol. 2020;258(6):1279–85. https://doi.org/10.1007/s00417-020-04661-4.

    Article  CAS  PubMed  Google Scholar 

  50. Lee JH, Lee WK. One-year results of adjunctive photodynamic therapy for type 1 neovascularization associated with thickened choroid. Retina. 2016;36(5):889–95. https://doi.org/10.1097/iae.0000000000000809.

    Article  CAS  PubMed  Google Scholar 

  51. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1–8.

    Article  CAS  Google Scholar 

  52. Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB. Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of ‘expanded spectra’ - a review. Clin Exp Ophthalmol. 2018;46(2):189–200. https://doi.org/10.1111/ceo.13114.

    Article  PubMed  Google Scholar 

  53. Lee WK, Baek J, Dansingani KK, Lee JH, Freund KB. Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness. Retina. 2016;36(Suppl 1):S73-s82. https://doi.org/10.1097/iae.0000000000001346.

    Article  PubMed  Google Scholar 

  54. •• Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am J Ophthalmol. 2019;204:80–9. https://doi.org/10.1016/j.ajo.2019.02.027. This prospective, multicenter, double-masked, sham-controlled randomized clinical study evaluated long-term efficacy and safety of intravitreal aflibercept monotherapy versus intravitreal aflibercept plus rescue photodynamic therapy in polypoidal choroidal vasculopathy.

    Article  CAS  PubMed  Google Scholar 

  55. Shields CL, Furuta M, Mashayekhi A, Berman EL, Zahler JD, Hoberman DM, et al. Visual acuity in 3422 consecutive eyes with choroidal nevus. Arch Ophthalmol. 2007;125(11):1501–7. https://doi.org/10.1001/archopht.125.11.1501.

    Article  PubMed  Google Scholar 

  56. Munie MT, Demirci H. Management of choroidal neovascular membranes associated with choroidal nevi. Ophthalmol Retina. 2018;2(1):53–8. https://doi.org/10.1016/j.oret.2017.04.002.

    Article  PubMed  Google Scholar 

  57. Pointdujour-Lim R, Mashayekhi A, Shields JA, Shields CL. Photodynamic therapy for choroidal nevus with subfoveal fluid. Retina. 2017;37(4):718–23. https://doi.org/10.1097/iae.0000000000001202.

    Article  PubMed  Google Scholar 

  58. García-Arumí J, Amselem L, Gunduz K, Badal J, Adan A, Zapata MA, et al. Photodynamic therapy for symptomatic subretinal fluid related to choroidal nevus. Retina. 2012;32(5):936–41. https://doi.org/10.1097/IAE.0b013e318232c366.

    Article  PubMed  Google Scholar 

  59. Barbazetto I, Schmidt-Erfurth U. Photodynamic therapy of choroidal hemangioma: two case reports. Graefes Arch Clin Exp Ophthalmol. 2000;238(3):214–21.

    Article  CAS  Google Scholar 

  60. Schmidt-Erfurth UM, Michels S, Kusserow C, Jurklies B, Augustin AJ. Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results. Ophthalmology. 2002;109(12):2284–94.

    Article  Google Scholar 

  61. Jurklies B, Anastassiou G, Ortmans S, Schuler A, Schilling H, Schmidt-Erfurth U, et al. Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophthalmol. 2003;87(1):84–9.

    Article  CAS  Google Scholar 

  62. Di Nicola M, Williams BK Jr, Srinivasan A, Al-Dahmash S, Mashayekhi A, Shields JA, et al. Photodynamic therapy for circumscribed choroidal hemangioma in 79 consecutive patients: comparative analysis of factors predictive of visual outcome. Ophthalmol Retina. 2020;4(10):1024–33. https://doi.org/10.1016/j.oret.2020.04.018.

    Article  PubMed  Google Scholar 

  63. Mathis T, Jardel P, Loria O, Delaunay B, Nguyen AM, Lanza F, et al. New concepts in the diagnosis and management of choroidal metastases. Prog Retin Eye Res. 2019;68:144–76. https://doi.org/10.1016/j.preteyeres.2018.09.003.

    Article  PubMed  Google Scholar 

  64. Kaliki S, Shields CL, Al-Dahmash SA, Mashayekhi A, Shields JA. Photodynamic therapy for choroidal metastasis in 8 cases. Ophthalmology. 2012;119(6):1218–22. https://doi.org/10.1016/j.ophtha.2011.12.024.

    Article  PubMed  Google Scholar 

  65. Ghodasra DH, Demirci H. Photodynamic therapy for choroidal metastasis. Am J Ophthalmol. 2016;161:104-9 e1-2. https://doi.org/10.1016/j.ajo.2015.09.033.

    Article  PubMed  Google Scholar 

  66. Shields CL, Khoo CTL, Mazloumi M, Mashayekhi A, Shields JA. Photodynamic therapy for choroidal metastasis tumor control and visual outcomes in 58 cases: the 2019 Burnier International Ocular Pathology Society Lecture. Ophthalmol Retina. 2020;4(3):310–9. https://doi.org/10.1016/j.oret.2019.10.009.

    Article  PubMed  Google Scholar 

  67. Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology. 2002;109(7):1256–66.

    Article  Google Scholar 

  68. Stattin M, Kralinger M, Haas G, Zehetner C, Bechrakis EN. Photodynamic therapy for retinal capillary hemangioblastoma. Can J Ophthalmol. 2014;49(1):e32–5. https://doi.org/10.1016/j.jcjo.2013.11.009.

    Article  PubMed  Google Scholar 

  69. Di Nicola M, Williams BK Jr, Hua J, Bekerman VP, Mashayekhi A, Shields JA, et al. Photodynamic therapy (PDT) for retinal hemangioblastoma: treatment outcomes in 17 consecutive patients. Ophthalmol Retina. 2021. https://doi.org/10.1016/j.oret.2021.04.007.

    Article  PubMed  Google Scholar 

  70. Schnurrbusch UEK, Jochman C, Einbock W, Wolf S. Complications after photodynamic therapy. Arch Ophthalmol. 2005;123(10):1347–50.

    Article  Google Scholar 

  71. Mennel S, Meyer CH, Eggarter F, Peter S. Transient serous retinal detachment in classic and occult choroidal neovascularization after photodynamic therapy. Am J Ophthalmol. 2005;140(4):758–60.

    Article  Google Scholar 

  72. Klais CM, Ober MD, Freund KB, Ginsburg LH, Luckie A, Mauget-Faÿsse M, et al. Choroidal infarction following photodynamic therapy with verteporfin. Arch Ophthalmol. 2005;123(8):1149–53.

    Article  Google Scholar 

  73. Kim SW, Oh J, Oh IK, Huh K. Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2009;40(3):300e303.

    Article  Google Scholar 

  74. Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111(8):1576e1584.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ocular Oncology Service, Department of Ophthalmology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Suite 5415, Cincinnati, OH, 45267-0527, USA

    Maura Di Nicola & Basil K. Williams Jr

Authors
  1. Maura Di Nicola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Basil K. Williams Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Basil K. Williams Jr.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Retina

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Di Nicola, M., Williams, B.K. Current Indications for Photodynamic Therapy in Retina and Ocular Oncology. Curr Ophthalmol Rep 9, 107–116 (2021). https://doi.org/10.1007/s40135-021-00272-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40135-021-00272-2

Keywords

Search

Navigation